Covid 19 Research using Clinical Trials (Home Page)
CYNK-001Wiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug377 | Hydroxychloroquine Sulfate + Azithromycin Wiki | 1.00 |
| drug375 | Hydroxychloroquine Sulfate Wiki | 0.32 |
Correlated MeSH Terms (14)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007154 | Immune System Diseases NIH | 1.00 |
| D030341 | Nidovirales Infections NIH | 0.71 |
| D012327 | RNA Virus Infections NIH | 0.71 |
| D003333 | Coronaviridae Infections NIH | 0.58 |
| D008171 | Lung Diseases, NIH | 0.50 |
| D012140 | Respiratory Tract Diseases NIH | 0.38 |
| D012141 | Respiratory Tract Infections NIH | 0.26 |
| D011024 | Pneumonia, Viral NIH | 0.17 |
| D003141 | Communicable Diseases NIH | 0.12 |
| D014777 | Virus Diseases NIH | 0.11 |
| D011014 | Pneumonia NIH | 0.08 |
| D007239 | Infection NIH | 0.08 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.07 |
| D018352 | Coronavirus Infections NIH | 0.06 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in hospitalized patients with moderate COVID-19 disease.
NCT04365101 Coronavirus Coronavirus Infection Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia Pneumonia, Viral Lung Diseases Respiratory Tract Disease Respiratory Tract Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Virus Disease Immunologic Disease ARDS Immunologic Factors Physiological Effects of Drugs Antiviral Agents Anti-infective Agents Analgesics Antimetabolites, Antineoplastic Biological: CYNK-001 MeSH:Infection Communicable Diseases Respiratory Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome RNA Virus Infections Pneumonia, Viral Coronaviridae Infections Nidovir Nidovirales Infections Pneumonia Lung Diseases Virus Diseases Respiratory Tract Diseases Immune System Diseases
HPO:Abnormal lung morphology Pneumonia Respiratory tract infection
Primary Outcomes
Description: Number and severity of adverse events
Measure: Phase 1: Frequency and Severity of Adverse Events (AE) Time: Up to 12 months
Description: Time from the date of randomization to the clearance of SARS-CoV-2 by rRT-PCR
Measure: Time to Clearance of SARS-CoV-2 Time: Up to 12 months
Description: Proportion of subjects with "negative" measurement of COVID-19 by rRT-PCR
Measure: Rate of Clearance of SARS-CoV-2 Time: Up to 12 months
Description: Time from the date of randomization to the first date of clinical improvement of cough.
Measure: Time to Clinical Improvement of cough Time: Up to 28 days
Description: Time from the date of randomization to the first date of clinical improvement of fever
Measure: Time to Clinical Improvement of fever Time: Up to 28 days
Description: Time from the date of randomization to the first date of clinical improvement of radiological evaluation of disease related chest x-ray
Measure: Time to Clinical Improvement in radiological evaluation of disease related chest x-ray Time: Up to 28 days
Description: Proportion of subjects who achieved clinical improvement of fever
Measure: Rate of Clinical Improvement of fever Time: Up to 28 days
Description: Proportion of subjects who achieved clinical improvement of cough
Measure: Rate of Clinical Improvement of cough Time: Up to 28 days
Description: Proportion of subjects who achieved clinical improvement of radiological evaluation of disease related chest x-ray
Measure: Rate of Clinical Improvement of radiological evaluation of disease related chest x-ray Time: Up to 28 days
Description: Time from randomization to the date of disappearance of virus from lower respiratory tract infection (LRTI) specimen where it has previously been found (induced sputum, endotracheal aspirate).
Measure: Time to Pulmonary Clearance Time: Up to 28 days
Description: Proportion of subjects who achieve pulmonary clearance
Measure: Rate of Pulmonary Clearance Time: Up to 28 days
Description: Assess the impact of CYNK-001 on changes in sequential organ failure assessment (SOFA) score.
Measure: Impact of CYNK-001 on sequential organ failure assessment (SOFA) score Time: Up to 28 days
Secondary Outcomes
Description: Number and severity of adverse events
Measure: Phase 2: Frequency and Severity of Adverse Events (AE) Time: up to 12 months
Description: Time to medical discharge as an assessment of overall clinical benefit
Measure: Overall Clinical Benefit by time to medical discharge Time: up to 12 months
Description: Hospital utilization will be measured as an assessment of overall clinical benefit
Measure: Overall Clinical Benefit by hospital utilization Time: up to 12 months
Description: Mortality rate will be measured as an assessment of overall clinical benefit
Measure: Overall Clinical Benefit by measuring mortality rate Time: up to 12 months
Related HPO nodes (Using clinical trials)
HP:0002088: Abnormal lung morphology
Genes 1201
GPC3 ARID1B NFKBIA POLR3H TNFRSF11A GLI3 CLPB BIRC3 IL17RA ZFPM2 WDR34 CTSC BTK FCGR3A PORCN STRA6 PIGL FRAS1 PHGDH SLC18A3 STAT3 TERT CFTR TAF1 GLI1 CFTR PRKCD DNAAF4 EGFR TGFB1 LEPR SLC18A3 ZMPSTE24 COL2A1 DICER1 PEPD DLL3 NGLY1 TERC WAS MARS1 TTC21B DNAAF2 SELENON IRAK4 SFTPA2 ARMC4 FBN1 GBA RSPH1 DYNC2LI1 SLC2A10 ALOX12B DNAL1 TINF2 UNG DHCR24 ADAMTS2 IL2RB NKX2-1 HOXD13 SFTPB KIAA0586 SPINK5 HIRA GBA GAS8 CEP57 CFAP298 WDR60 GNPTAB KRAS LEP MCTP2 KAT6B PUF60 CD3G FCN3 CYBA TBL1XR1 DOK7 CHRND SMN1 EP300 BUB1B DOCK8 EFEMP2 ESS2 SMPD1 SCNN1G CSF2RA RBPJ BCOR HLA-DPB1 KAT6B DNAAF1 ICOS KIF11 MEFV SPAG1 CCDC40 TRAIP CARD11 RSPH4A IL10 LZTR1 CHRNG PTPRC NOTCH3 SNORD115-1 NOTCH3 ARVCF BACH2 RLIM RAG2 ITCH DGCR6 MST1 FCGR2A TBX5 CD28 IDUA SLC25A22 STN1 MGP CD8A SULT2B1 CHST14 JMJD1C TPM2 CCDC103 HELLS FCGR2A MRPS22 SLC5A7 CEP55 SDR9C7 HERC2 GPC6 TGFBR1 STAT3 TTC37 CD247 MESP2 GTF2I CDC45 BLNK IGH CCNQ KIAA0586 BLNK FOXP1 MAT2A SMARCA4 SGCG FAM20C PRKN MPLKIP NPAP1 FOXE3 NCF1 SMAD4 CYP4F22 TPP2 RNU4ATAC EIF2AK4 STAT6 NGLY1 LRBA DNMT3B CCR6 GATA6 P4HTM TRPS1 COL13A1 MIF C1R DNAAF5 SFTPB CD81 CARMIL2 GATA6 CCNQ TAP1 FGFR3 SFTPC MESP2 SMAD4 SNX10 DOCK8 SHROOM4 WDR35 GRIP1 ETFB MARS1 FLNB LETM1 TERT APOE SMPD1 CSF2RB CTLA4 SCN10A GREB1L ITGA8 NPM1 LGI4 MYH3 CR2 ARID1B SERPINF2 NHLRC2 GPC4 COL1A1 DCLRE1C NDN SGSH LRRC56 LRRC6 HPS4 BTNL2 CCDC40 ALG9 TMEM94 BTK DGCR8 CCBE1 EWSR1 WDR60 PGM3 COG4 PSAP HES7 SCN9A CFB KIAA0319L LMNA HLA-DRB1 RBM10 EFEMP2 MRAS SMARCC2 AGGF1 COL6A2 POLR3A GTF2E2 SMAD3 ALDH18A1 WRAP53 INVS ITGA3 CFI HLA-B FBLN5 DNAI2 MINPP1 FAS SLC26A2 ZAP70 DCTN4 NR5A1 CD79B NEK9 FREM2 ARHGAP31 KIF1A AFF4 BTNL2 CYP2A6 DONSON WDR34 GLA TIRAP STAT3 CCDC114 ACVRL1 PTEN DLL4 ZBTB16 GATA6 HYLS1 PIK3R1 HACD1 DPM2 KITLG RMRP DNAH11 STAT5B ERF EPM2A HYDIN G6PC3 ATM COL5A2 SNORD116-1 DNAH11 NFKB2 EPG5 BCL10 CCR1 SON ERCC2 AK2 RASA2 STRA6 SLC35A1 MS4A1 DNAAF3 REN MYH3 CCDC151 LIG4 MKKS ATP11A FBLN5 ATP6V0A2 BMPR2 SLC22A18 SOS1 RFC2 PPP2R1B TGFBR2 IFT81 WIPF1 GATA4 LFNG RAF1 NOP10 RFXANK RSPH4A HLA-B SLC52A3 NHP2 CXCR4 GSN PCNT TNFRSF13B LEP TERC CORO1A CCDC65 PTPN22 CD55 TGFBR1 IL17F ALG12 STAT4 COL11A2 MEFV NHLRC1 ABCA12 LTBP3 SCNN1B DVL3 HLA-DRB1 RPL10 NSD2 RARB TECPR2 CCBE1 EPG5 VANGL1 FLNA CCDC39 RFXANK BMPR2 CARD11 SFTPC CFH OFD1 ITCH MYH11 JAGN1 PRKAR1A LRRC6 NAA10 ITPR1 CFTR GLE1 PLP1 GPR35 INTU STAT1 NR2F2 CYBC1 ABL1 SLC35A1 HLA-DPA1 LBR PSMC3IP BRAF CASP10 RAG2 TERT CACNA1C HLA-DRB1 PHGDH CHRNA1 TRIP13 MYD88 IDUA B3GLCT NOTCH2 TAPT1 KIAA0556 AICDA CLCN7 PANK2 PAX6 MKS1 RANBP2 FARSB FGF20 FLNA ELN CIITA RSPH3 ADA DNAAF2 PLVAP BCL2 EMG1 KMT2D ZNF341 TNFRSF1A IL7R LEPR NAGLU RAG2 MESP2 CD46 WT1 ELN SCNN1A PERP HLA-DRB1 DIS3L2 DLL3 MITF CSF2RA LAMTOR2 BRAF RAG1 BLM CCR6 NSMCE3 UMPS INHBA ELN IL23R RFX5 GRHL3 IL6 LIPN WT1 TTC25 FGFR3 ADA LMNA TTC25 ACTA1 TP53 ZAP70 LOX UFD1 ALPL IGHM SCNN1G STAT3 COL3A1 RAG2 NBN FLCN LIFR TGM1 PIK3CA CACNA1B ATP5F1A GPKOW ARMC4 TREX1 NCF1 SNAP25 SERPINH1 IPW FADD CXCR4 TSC2 CD3E BUB1 MCM4 CFAP221 ERAP1 CTC1 DNAI2 KCNJ6 COPA NOTCH1 SPINK1 CCDC114 DOCK6 PLG ABCA3 SLC25A24 SOX10 LRRC8A FAS ICOS POLA1 VPS33A PRKAR1A FCGR2B CHAT PAX3 CCNO ALMS1 NCF2 ITGA8 GLB1 CHRM3 TNFRSF13C ERCC3 EVC FADD CTLA4 CD79A BMP15 H19 RSPH9 NEK8 CFTR NCF2 FLNB FASLG MAP3K8 RIT1 MECP2 TERC KLHL40 CCND1 HLA-DRB1 IKBKB DNAAF3 TP53 MAGEL2 CCN2 ACP5 CHAMP1 HYDIN TINF2 EOGT MTHFD1 SMARCB1 ABCA3 RAG1 PIK3R1 TERT PWAR1 SCARB2 OCRL MS4A1 DNAAF6 PIK3R1 CCDC39 UBE2A NKX2-1 TCF4 ACTA2 ARID2 ZBTB24 UBAC2 FRAS1 TINF2 ETFDH WDR19 GNPTAB C4A NFIX RAG2 PTEN SCNN1A RFXAP USP9X NFKB1 NIPAL4 WRN IL2RG POLE MEFV KLHL41 PKHD1 AGT TGFBR2 INPPL1 GBA MYBPC3 GUSB CITED2 CTRC CSPP1 RHOH MCIDAS DCLRE1C TIMM8A DNAH9 PEX1 SIK1 GTF2H5 IER3IP1 GUSB EPHB4 COL2A1 TBC1D24 SPAG1 MSN GAS2L2 NIPBL NFKB1 CRELD1 BRCA2 IGLL1 RNF168 ZBTB24 RFX5 TERT MKRN3 RASGRP1 PLEC NOP10 BICC1 NSDHL MUSK ENG MBTPS2 DHCR7 IRAK4 COLQ TCTN3 MYO9A TBX1 DRC1 CC2D2A IRF2BP2 WNT4 HSPG2 TAP2 KEAP1 LAMA2 DICER1 WT1 CFAP300 RIPK4 DNAI1 TBCD RRAS2 IL2RG RELA SOX4 MFAP5 IFNGR1 NOD2 GLI3 TRPV3 ZMYND10 NRAS RFXAP FOXF1 DGCR2 RSPH9 PLOD1 SLC11A1 SLC7A7 SCNN1B PKD1L1 TRIM28 SLCO2A1 CLCA4 MLXIPL CLIP2 BMP2 CCDC65 DHCR24 POU6F2 SFTPA1 FIP1L1 SERPINA1 TRIP4 USB1 UBB FLCN LAMTOR2 TBC1D24 NECTIN1 SAMD9 CCNO AARS2 LMOD3 GLDN CIITA MUC5B LCK NPM1 MMP21 IFT172 COL5A1 TBL2 ASAH1 ALMS1 DNASE1 RUNX2 DNAAF4 SH3KBP1 NPHP3 CSPP1 DNAI1 IL12A-AS1 NABP1 TSC1 TNFRSF13C SEC24C TGFB2 IDUA IL2RG CCND1 DNAAF6 MYH7 GALNS NUMA1 FUCA1 RIPPLY2 B2M SFTPC FLI1 CD3E ELANE ASCC1 TCF3 SLC29A3 RELB ERCC6 ACTA1 FGFR1 LAMB2 COMT SPEF2 AGA ELN PYROXD1 CLEC7A NAA10 KRAS GPC3 SMPD1 SOX11 REST DDR2 BCL11B SLC7A7 NUP88 FLCN EDARADD SPECC1L FAM111B MYSM1 ARID1A GNS CD79B LYST PDGFRA SRP54 PIEZO2 BGN IL1RN GATA4 TRIP11 GBA SLC26A2 NUP107 NAA10 THOC2 SELENON RARB STX1A RTEL1 TNFRSF13B GP1BB SKIV2L VPS13A BCOR BCOR INPPL1 CAV1 AP3B1 EDNRB NOTCH2 GATA2 IRF5 CSF2RB TTC7A SDCCAG8 FANCB JAK3 TBCE RTEL1 OSTM1 VHL CCDC151 NEK1 IL21 SPP1 DNAJB13 JAK3 RNF125 INSR STK36 IL7R POLA1 CD19 FOXC2 CD3D RSPH3 TRIM28 FBLN5 SNAI2 TAPBP RAPSN CYBB CCN2 DRC1 VAMP1 ADNP WT1 PTPN22 IFT80 PTPN11 ARSB SP110 ZEB2 SLC25A1 ASAH1 PCGF2 SOS2 COQ7 COL6A1 GATA6 SLC46A1 EVC2 RRAS IKBKB LPIN2 TGFB2 GLE1 GAS2L2 RREB1 TGFB1 PEPD RNU4ATAC STK11 MYL2 SCN11A C1QA ERBB2 TSC2 KLRC4 PSAT1 MYT1 DICER1 SCNN1B BTK CCDC22 DSP CFTR RYR1 ADAMTS3 CD81 WDR60 PLG SYT2 USP9X DKC1 GLI3 LMNA PRPS1 ELANE C11ORF95 WNT3 ALB RSPO2 IFT80 NME8 ATP6V1E1 TNFRSF13C RPS15A MAP3K20 DYNC2H1 TNFSF12 KAT6B ADA SMARCE1 FASLG DSG1 ELN RPGR IFT43 CREBBP PRTN3 COL3A1 LTBP4 NFE2L2 FLNA BMPER RIT1 RCBTB1 GAS8 FBN1 DPF2 BAZ1B CASP8 EHMT1 KRAS LACC1 ARHGAP31 PRSS2 CRELD1 NFKB2 WDR35 ZMYND10 IL17RA TARS1 NXN FANCB COL6A3 TCIRG1 WASHC5 CHRNG ETFA GDF1 DPP9 NME8 IL17RC AGRN CHRNG CDT1 RPGR TBX1 CBL NADK2 GTF2IRD1 PML IRF1 ABCA12 LAT IFT140 PTPN11 MANBA PARN GFI1 NBN RARA RNF113A HELLPAR PMM2 SPIDR SCNN1A ICOS TNFSF12 PWRN1 MGP USB1 TYK2 IL21R FMO3 AGA IRF5 FSHR MYRF SLC34A2 RIPK1 DNAAF1 HPGD ORC6 HPS6 NPHP3 GMNN RB1 RYR1 CFAP298 JAG1 TNFRSF13B KDM6A TSC1 SAMD9L GDF1 ROR2 WNT4 ACE TPM3 WDR34 FBN1 GBA CFI BUB3 COG4 PPP1CB TSC2 PRKG1 MYLK MUSK IGHM TSC1 TRAF3IP2 RAF1 CEP120 PGM3 IL12A TNFRSF1B DNASE1L3 EGFR ELP1 ELN FLCN PNP DNAH5 HGSNAT SETBP1 ECM1 PIGN CR2 MASP2 RTEL1 SFTPA2 AP3D1 MBTPS2 RAC1 CRTAP PIGN KAT6B IFIH1 DNAAF5 BRAF ADGRG6 FAT4 SNRPN DYNC2H1 SOX18 CD19 ACADVL TNFSF11 CYBB PTPN22 PEX13 TRIP13 TK2 AKT1 SLC2A10 GAA PRKDC ALOXE3 CR2 CYBA FUZ RAG1 PTH1R MUC5B CDCA7 LMNA TERC RAG1 CD19 CD79A DNAH5 TFRC PIEZO1 FOXP3 IRF8 NEB LYST EXOSC9 A2ML1 CD3D CRKL RYR1 NKX2-5 BAP1 TGFB3 PDGFRB DCLRE1C PARN CTLA4 CEP120 PRKAG2 DCLRE1C SLC26A2 TGFB1 CTLA4 XIAP RSPO2 IL7R TRPV4 BCL6 IKBKG FOXJ1 NELFA ZMPSTE24 IL2RG CASP8 TMEM260 RAG1 IGLL1 CFAP410 CAV1 HPS1 SERPINA1 FOXE1 UNC119 RSPH1 LIMK1 MYOD1 DYNC2LI1 RAG1 SLC26A2 PARN TRIP4 STAT1 DNAH1 FAS WDR19 DHCR7 WAS CCDC103 IL2RA TLR4 SLC12A6 ACTA1 ATM RET LRRC56 RAB3GAP2 PIGN FGF20 STAT4 IKZF1 PRKCD SLC35C1 HFE MKRN3-AS1 SH2D1A HABP2 NAB2 NCF4 XIAP MAPK1 FSHR CHD7 IGH AGTR1 WNT3 BLM HLA-DRB1 SMARCD2 NKX2-5 TBX6 STING1 ELP1 OFD1 COL13A1 NHP2 RAB27A MYO5A DKC1 FAM13A COL11A2 TRIP11 HRAS IRAK1 PRSS1 GRIP1 PLCG2 NCF4 ZNHIT3 MALT1 SCNN1G BCR NRAS TCIRG1 MEFV SOX18 TBC1D23 CEP57 SERPINF2 DNAJB13 PIK3CD FAT4 TBX1 ITGA7 RNF168 SMN1 TERT DNMT3B SMAD3 NFKB2 HP:0002090: Pneumonia
Genes 208
TIMM8A DNAH9 GAS8 DNAH11 TNFRSF11A TBC1D24 SPAG1 MS4A1 GAS2L2 CCDC151 NIPBL BTK LIG4 NFKB2 TCIRG1 IGLL1 RNF168 STAT3 TAF1 RSPH4A CFTR NME8 DNAAF4 LEP CCDC65 NADK2 CD55 COL11A2 NHLRC1 PEPD CFAP300 LTBP3 WAS DNAI1 TBCD IL2RG GFI1 NBN RSPH1 CCDC39 PMM2 ICOS TNFSF12 IFNGR1 CARD11 SFTPC DNAL1 OFD1 ZMYND10 IL21R FMO3 SLC35A1 PLOD1 ORC6 RAG2 CACNA1C GAS8 RYR1 CFAP298 GNPTAB TNFRSF13B KDM6A PANK2 RANBP2 CYBA USB1 UBB DOCK8 ADA DNAAF2 KMT2D SAMD9 MUC5B IL7R DNAAF1 ICOS RAG2 CARD11 PTPRC ALMS1 NOTCH3 NSMCE3 DNAI1 TNFRSF13C GRHL3 EGFR IL2RG DNAAF6 PNP DNAH5 SETBP1 CR2 CD3E ADA MASP2 SFTPA2 ACTA1 RAC1 TTC25 FCGR2A ZAP70 SPEF2 IGHM DNAAF5 NBN CD247 DDR2 CD19 ACADVL KIAA0586 TK2 BLNK ARMC4 SGCG RAG1 CXCR4 NCF1 SRP54 FOXP3 IRF8 CFAP221 RNU4ATAC KCNJ6 LRBA CD3D P4HTM SELENON CCDC114 TNFRSF13B PLG DCLRE1C SLC25A24 DCLRE1C ICOS IL7R FOXJ1 JAK3 IL2RG CASP8 RAG1 OSTM1 CFAP410 CCNO NCF2 UNC119 TNFRSF13C JAK3 RNF125 STK36 POLA1 CD19 CR2 DNAH1 RSPH3 RSPH9 CYBB DRC1 DCLRE1C CCDC103 DNAAF3 LRRC56 PIGN LRRC6 SP110 PRKCD ACP5 CCDC40 SLC35C1 BTK MTHFD1 PGM3 RAG1 TERT CHD7 CFB TGFB1 RNU4ATAC SMARCD2 NKX2-1 OFD1 ZBTB24 BTK DNAI2 WDR19 ZAP70 CD79B CD81 COL11A2 NFIX RAG2 ELANE AFF4 NFKB1 IL2RG TNFRSF13C TNFSF12 CCDC114 ADA GBA DNAJB13 RPGR CSPP1 RMRP EPM2A DNMT3B NFKB2 MCIDAS HYDIN SNP 0
HP:0011947: Respiratory tract infection
Genes 633
TIMM8A DNAH9 SIK1 ARID1B NFKBIA GTF2H5 IER3IP1 TNFRSF11A GUSB TBC1D24 BIRC3 IL17RA SPAG1 MSN WDR34 CTSC GAS2L2 NIPBL BTK NFKB1 FCGR3A CRELD1 IGLL1 RNF168 ZBTB24 STAT3 RFX5 TAF1 MKRN3 PLEC CFTR IRAK4 COLQ DNAAF4 TCTN3 MYO9A TGFB1 LEPR SLC18A3 TAP2 LAMA2 PEPD NGLY1 CFAP300 WAS DNAI1 TBCD DNAAF2 SELENON IL2RG IRAK4 ARMC4 SOX4 RSPH1 IFNGR1 GLI3 ALOX12B DNAL1 ZMYND10 UNG NRAS RFXAP IL2RB NKX2-1 RSPH9 PLOD1 SPINK5 SCNN1B GBA GAS8 CFAP298 CLCA4 GNPTAB LEP CLIP2 CCDC65 CD3G FCN3 CYBA SMN1 TRIP4 EP300 USB1 UBB DOCK8 LAMTOR2 TBC1D24 NECTIN1 SAMD9 SCNN1G CCNO CIITA MUC5B HLA-DPB1 DNAAF1 LCK ICOS NPM1 SPAG1 CCDC40 TRAIP CARD11 RSPH4A TBL2 ASAH1 PTPRC ALMS1 RUNX2 DNAAF4 NOTCH3 SH3KBP1 SNORD115-1 DNAI1 BACH2 RAG2 TSC1 TNFRSF13C IDUA IL2RG DNAAF6 GALNS IDUA SLC25A22 FUCA1 B2M SFTPC FLI1 CD3E MGP CD8A ELANE SULT2B1 TCF3 SLC29A3 RELB TPM2 CCDC103 ACTA1 HELLS FCGR2A LAMB2 SLC5A7 SPEF2 AGA SDR9C7 PYROXD1 CLEC7A HERC2 KRAS SMPD1 SOX11 CD247 MESP2 DDR2 GTF2I BLNK KIAA0586 BLNK FOXP1 SMARCA4 EDARADD SGCG MYSM1 ARID1A GNS CD79B MPLKIP LYST NPAP1 NCF1 CYP4F22 SRP54 TPP2 RNU4ATAC TRIP11 NGLY1 LRBA DNMT3B P4HTM SELENON STX1A TRPS1 COL13A1 TNFRSF13B DNAAF5 VPS13A CD81 INPPL1 CARMIL2 TAP1 NOTCH2 MESP2 GATA2 SNX10 CSF2RB SDCCAG8 JAK3 TBCE DOCK8 SHROOM4 RTEL1 OSTM1 CCDC151 LETM1 SMPD1 IL21 DNAJB13 JAK3 RNF125 INSR STK36 SCN10A IL7R MYH3 POLA1 CD19 CR2 ARID1B CD3D RSPH3 TAPBP CYBB DRC1 VAMP1 ADNP DCLRE1C PTPN22 NDN SGSH ARSB LRRC56 LRRC6 SP110 CCDC40 SLC25A1 ASAH1 PCGF2 BTK CCBE1 COL6A1 GATA6 PGM3 COG4 PSAP SLC46A1 SCN9A IKBKB CFB GAS2L2 TGFB1 PEPD SMARCC2 RNU4ATAC MYL2 SCN11A COL6A2 POLR3A GTF2E2 TSC2 WRAP53 ITGA3 CFI SCNN1B BTK CCDC22 DNAI2 CFTR ZAP70 DCTN4 CD79B RYR1 ADAMTS3 CD81 PLG SYT2 USP9X DKC1 KIF1A PRPS1 ELANE AFF4 ALB NME8 TNFRSF13C MAP3K20 TNFSF12 TIRAP STAT3 CCDC114 ADA SMARCE1 DSG1 PIK3R1 RPGR CREBBP HACD1 PRTN3 NFE2L2 DPM2 FLNA RMRP DNAH11 ERF EPM2A HYDIN G6PC3 ATM GAS8 SNORD116-1 DNAH11 NFKB2 EPG5 BCL10 DPF2 BAZ1B ERCC2 AK2 EHMT1 MS4A1 DNAAF3 CCDC151 LIG4 NFKB2 FBLN5 ZMYND10 ATP6V0A2 IL17RA TARS1 NXN COL6A3 TCIRG1 RFC2 WASHC5 WIPF1 GATA4 NOP10 RFXANK RSPH4A HLA-B SLC52A3 NME8 NHP2 CXCR4 GSN PCNT TNFRSF13B LEP IL17RC AGRN CORO1A CCDC65 RPGR NADK2 CD55 GTF2IRD1 IL17F ALG12 COL11A2 NHLRC1 ABCA12 LTBP3 SCNN1B ABCA12 NSD2 TECPR2 MANBA PARN GFI1 EPG5 NBN FLNA RNF113A CCDC39 PMM2 SCNN1A ICOS RFXANK TNFSF12 PWRN1 CARD11 SFTPC MGP USB1 OFD1 JAGN1 LRRC6 TYK2 IL21R FMO3 CFTR AGA PLP1 STAT1 NR2F2 CYBC1 SLC35A1 HLA-DPA1 RIPK1 DNAAF1 ORC6 RAG2 HPS6 CACNA1C GMNN IDUA RYR1 CFAP298 KIAA0556 TNFRSF13B AICDA KDM6A CLCN7 PANK2 SAMD9L RANBP2 ROR2 ELN CIITA TPM3 RSPH3 ADA DNAAF2 KMT2D ZNF341 GBA TNFRSF1A IL7R LEPR NAGLU RAG2 COG4 SCNN1A IGHM DLL3 TRAF3IP2 CSF2RA LAMTOR2 BLM NSMCE3 UMPS PGM3 RFX5 GRHL3 EGFR ELP1 PNP LIPN DNAH5 HGSNAT SETBP1 ECM1 TTC25 CR2 ADA MASP2 SFTPA2 AP3D1 MBTPS2 RAC1 TTC25 KAT6B ZAP70 IFIH1 ALPL IGHM SCNN1G DNAAF5 RAG2 NBN FAT4 SNRPN CD19 TGM1 ACADVL TNFSF11 CYBB PTPN22 PEX13 TK2 CACNA1B GAA PRKDC ARMC4 ALOXE3 CR2 CYBA RAG1 NCF1 SNAP25 CDCA7 IPW CXCR4 TERC RAG1 CD19 CD3E CD79A DNAH5 TFRC MCM4 FOXP3 IRF8 CFAP221 CTC1 LYST DNAI2 KCNJ6 EXOSC9 CD3D CRKL RYR1 CCDC114 PLG DCLRE1C SLC25A24 DCLRE1C LRRC8A ICOS TGFB1 CTLA4 XIAP IL7R IKBKG VPS33A FOXJ1 NELFA IL2RG CASP8 RAG1 CHAT IGLL1 CFAP410 CCNO ALMS1 NCF2 UNC119 GLB1 CHRM3 RSPH1 TNFRSF13C ERCC3 LIMK1 CTLA4 CD79A RAG1 SLC26A2 STAT1 DNAH1 RSPH9 CFTR NCF2 WAS MECP2 CCDC103 IL2RA SLC12A6 ACTA1 IKBKB ATM DNAAF3 LRRC56 RAB3GAP2 PIGN MAGEL2 IKZF1 PRKCD ACP5 CHAMP1 SLC35C1 MKRN3-AS1 HYDIN SH2D1A MTHFD1 SMARCB1 NCF4 RAG1 XIAP MAPK1 PIK3R1 TERT PWAR1 CHD7 IGH OCRL MS4A1 DNAAF6 PIK3R1 SMARCD2 CCDC39 TBX6 UBE2A STING1 NKX2-1 ELP1 OFD1 COL13A1 ARID2 ZBTB24 TINF2 MYO5A WDR19 GNPTAB COL11A2 NFIX RAG2 SCNN1A RFXAP PLCG2 USP9X NFKB1 NIPAL4 NCF4 ZNHIT3 MALT1 SCNN1G IL2RG BCR POLE TCIRG1 INPPL1 TBC1D23 GBA DNAJB13 GUSB PIK3CD ITGA7 CSPP1 SMN1 TERT DNMT3B NFKB2 MCIDAS DCLRE1C Protein Mutations 1
H275Y SNP 0
Primary Outcomes
Description: Number and severity of adverse events
Measure: Phase 1: Frequency and Severity of Adverse Events (AE) Time: Up to 12 monthsDescription: Time from the date of randomization to the clearance of SARS-CoV-2 by rRT-PCR
Measure: Time to Clearance of SARS-CoV-2 Time: Up to 12 monthsDescription: Proportion of subjects with "negative" measurement of COVID-19 by rRT-PCR
Measure: Rate of Clearance of SARS-CoV-2 Time: Up to 12 monthsDescription: Time from the date of randomization to the first date of clinical improvement of cough.
Measure: Time to Clinical Improvement of cough Time: Up to 28 daysDescription: Time from the date of randomization to the first date of clinical improvement of fever
Measure: Time to Clinical Improvement of fever Time: Up to 28 daysDescription: Time from the date of randomization to the first date of clinical improvement of radiological evaluation of disease related chest x-ray
Measure: Time to Clinical Improvement in radiological evaluation of disease related chest x-ray Time: Up to 28 daysDescription: Proportion of subjects who achieved clinical improvement of fever
Measure: Rate of Clinical Improvement of fever Time: Up to 28 daysDescription: Proportion of subjects who achieved clinical improvement of cough
Measure: Rate of Clinical Improvement of cough Time: Up to 28 daysDescription: Proportion of subjects who achieved clinical improvement of radiological evaluation of disease related chest x-ray
Measure: Rate of Clinical Improvement of radiological evaluation of disease related chest x-ray Time: Up to 28 daysDescription: Time from randomization to the date of disappearance of virus from lower respiratory tract infection (LRTI) specimen where it has previously been found (induced sputum, endotracheal aspirate).
Measure: Time to Pulmonary Clearance Time: Up to 28 daysDescription: Proportion of subjects who achieve pulmonary clearance
Measure: Rate of Pulmonary Clearance Time: Up to 28 daysDescription: Assess the impact of CYNK-001 on changes in sequential organ failure assessment (SOFA) score.
Measure: Impact of CYNK-001 on sequential organ failure assessment (SOFA) score Time: Up to 28 daysSecondary Outcomes
Description: Number and severity of adverse events
Measure: Phase 2: Frequency and Severity of Adverse Events (AE) Time: up to 12 monthsDescription: Time to medical discharge as an assessment of overall clinical benefit
Measure: Overall Clinical Benefit by time to medical discharge Time: up to 12 monthsDescription: Hospital utilization will be measured as an assessment of overall clinical benefit
Measure: Overall Clinical Benefit by hospital utilization Time: up to 12 monthsDescription: Mortality rate will be measured as an assessment of overall clinical benefit
Measure: Overall Clinical Benefit by measuring mortality rate Time: up to 12 months